Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

39.44
+0.26000.66%
Volume:4.24M
Turnover:165.34M
Market Cap:45.95B
PE:65.73
High:39.64
Open:38.80
Low:38.25
Close:39.18
52wk High:40.79
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.97
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.93
PE(LYR):32.60

Loading ...

Teva Study Finds Only 23% of Younger Adults With Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed With TD Despite Widespread Impact

THOMSON REUTERS
·
May 18

Teva put volume heavy and directionally bearish

TIPRANKS
·
May 15

Teva, Upstart, Bloom, Corning, Seagate Insider Shock

TIPRANKS
·
May 09

Top Teva Executives Cash Out in Major Insider Stock Moves

TIPRANKS
·
May 08

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress

Simply Wall St.
·
May 07

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 06

Teva Earnings Call Highlights Innovative-Driven Margin Upswing

TIPRANKS
·
May 06

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally?

Simply Wall St.
·
May 06

Top Teva Executives Quietly Offload Major Stock Stakes

TIPRANKS
·
May 05

Leader Capital Markets Remains a Buy on Teva (TEVA)

TIPRANKS
·
May 01

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Apr 30

Truist Raises Price Target on Teva Pharmaceutical Industries to $45 From $42, Keeps Buy Rating

MT Newswires Live
·
Apr 30

Piper Sandler Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Apr 30

A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress

Simply Wall St.
·
Apr 30

Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside

TIPRANKS
·
Apr 30

Teva price target raised to $45 from $42 at Truist

TIPRANKS
·
Apr 30

Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Sector Update: Health Care

MT Newswires Live
·
Apr 29

Teva Pharmaceuticals Exec Says Co's Operations Remain Uninterrupted With No Material Impact on 2026 Guidance - Conf Call

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says It Is Difficult to Predict Whether There Will Be a Channel Drawdown Ahead of Price Changes Set to Take Effect in 2027

THOMSON REUTERS
·
Apr 29